Page 233 - Dc News Today

'House of the Dragon' star Milly Alcock cast as DCU's 'Supergirl.'

A new survey found that D.C. has some of the worst traffic in the country. In fact, the survey conducted by geolocation technology specialist TomTom found that D.C. is ranked as the second city with the worst traffic in the country. 

Regeneron Pharmaceuticals is paying $5 million up front for 2seventy bio’s cancer drug pipeline. 2seventy will now focus on a cell therapy commercialized with partner Bristol Myers Squibb while Regeneron adds assets for its newly formed cell therapy division.

Chronic pain, an enduring concern for many older adults, is no longer confined to the traditional realm of pharmaceuticals. While traditional pain management methods like medication were once the go-to approach, alternative therapies are emerging as a viable and holistic approach to addressing this issue.

Anne Osdoit, CEO of Moon Surgical, explains how the Maestro System may be expanding the surgical robotics pie by bringing the capability to newer markets and how surgical robotics do not have to break the bank.

Blue Shield of California Promise Health Plan is working with the GED Testing Service to help members earn a General Educational Development (GED) diploma for no cost. Members can register online and gain access to GED study materials in both English and Spanish.

Valendo Health, the newest startup built at Redesign Health, launched on Tuesday. The company partners with independent endocrinology practices and provides technology to help them thrive in value-based care arrangements.

Shift from the stock shelf to the digital shelf and invest today in additive manufacturing technology so medical facilities can easily create repeatable, durable PPE on-demand printing to accelerate the process of securely printing equipment for medical professionals.

Starting Monday, if you drive, stop or park in a designated bus lane in the nation’s capital – you could get a ticket.

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value. \